Cargando…

A genomic analysis of Philadelphia chromosome-negative AML arising in patients with CML

Detalles Bibliográficos
Autores principales:	Krysiak, K, Christopher, M J, Skidmore, Z L, Demeter, R T, Magrini, V, Kunisaki, J, O'Laughlin, M, Duncavage, E J, Miller, C A, Ozenberger, B A, Griffith, M, Wartman, L D, Griffith, O L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855253/ https://www.ncbi.nlm.nih.gov/pubmed/27058228 http://dx.doi.org/10.1038/bcj.2016.18

Ejemplares similares

A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia
por: Lu, Charles, et al.
Publicado: (2016)

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
por: Brattås, Marte Karen, et al.
Publicado: (2018)

PB1891: VARIANT PHILADELPHIA CHROMOSOME IN CML
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

Genomic Copy Number Variants in CML Patients With the Philadelphia Chromosome (Ph+): An Update
por: Zhang, Heyang, et al.
Publicado: (2021)

Isodicentric Philadelphia chromosome: an uncommon chromosomal abnormality in the chronic phase of chronic myeloid leukemia (CML)
por: Loo, Eric, et al.
Publicado: (2015)

A genomic case study of mixed fibrolamellar hepatocellular carcinoma
por: Griffith, O. L., et al.
Publicado: (2016)

Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing
por: Slade, Michael J., et al.
Publicado: (2023)

Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma
por: Barnell, Erica K., et al.
Publicado: (2022)

Nicotinamide–Ponatinib Analogues as Potent Anti-CML and Anti-AML Compounds
por: Larocque, Elizabeth, et al.
Publicado: (2020)

FISH mapping of Philadelphia negative BCR/ABL1 positive CML
por: Virgili, Anna, et al.
Publicado: (2008)

GenVisR: Genomic Visualizations in R
por: Skidmore, Zachary L., et al.
Publicado: (2016)

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

Cytogenetic and Molecular Analyses of Philadelphia Chromosome Variants in CML (chronic myeloid leukemia) Patients from Sindh using Karyotyping and RT-PCR
por: Ujjan, Ikram Din, et al.
Publicado: (2015)

On the Power of Additional and Complex Chromosomal Aberrations in CML
por: Greulich-Bode, Karin M, et al.
Publicado: (2012)

Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy()
por: Aliano, Stefania, et al.
Publicado: (2013)

Unraveling the chaotic genomic landscape of primary and metastatic canine appendicular osteosarcoma with current sequencing technologies and bioinformatic approaches
por: Chu, Shirley, et al.
Publicado: (2021)

The Philadelphia chromosome in leukemogenesis
por: Kang, Zhi-Jie, et al.
Publicado: (2016)

Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy
por: Uy, Geoffrey L., et al.
Publicado: (2016)

Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia
por: Kenderian, S S, et al.
Publicado: (2013)

Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
por: Bonifacio, Massimiliano, et al.
Publicado: (2021)

Covert Brain Infarcts in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders
por: Kuznetsova, Polina I., et al.
Publicado: (2021)

PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

Significance of non-standard Philadelphia chromosomes in chronic granulocytic leukaemia.
por: Potter, A. M., et al.
Publicado: (1981)

Philadelphia chromosome duplication as a ring-shaped chromosome
por: Borjas-Gutierrez, Cesar, et al.
Publicado: (2016)

Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia
por: Barnell, Erica K., et al.
Publicado: (2021)

What Is the Role of HSCT in Philadelphia-Chromosome–Positive and Philadelphia-Chromosome–Like ALL in the Tyrosine Kinase Inhibitor Era?
por: Vettenranta, Kim, et al.
Publicado: (2022)

PB1843: ACUTE MYELOID LEUKEMIA WITH PHILADELPHIA CHROMOSOME: EXPERIENCE OF SFAX HEMATOLOGY DEPARTMENT
por: Siala, N., et al.
Publicado: (2022)

Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma
por: Gomez, Felicia, et al.
Publicado: (2023)

New concepts for CML clonality
por: Khorashad, Jamshid S., et al.
Publicado: (2013)

Significance of gain and loss of chromosomal abnormalities in AML: an Indian experience
por: Trivedi, Pina J, et al.
Publicado: (2014)

Chromosomal rearrangements in acute myeloid leukemia (AML)
por: Belloni, E, et al.
Publicado: (2010)

Significance Analysis of Microarrays (SAM) Offers Clues to Differences Between the Genomes of Adult Philadelphia Positive ALL and the Lymphoid Blast Transformation of CML
por: Grace, Colin, et al.
Publicado: (2012)

Sudden extramedullary and extranodal Philadelphia-positive anaplastic large-cell lymphoma transformation during imatinib treatment for CML: A case report
por: Wu, Qiong, et al.
Publicado: (2022)

Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood
por: Koo, Hong Hoe
Publicado: (2011)

PB2054: HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Holik, H., et al.
Publicado: (2022)

Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Bernt, Kathrin M., et al.
Publicado: (2014)

High-risk additional chromosomal abnormalities at low blast counts herald death by CML
por: Hehlmann, Rüdiger, et al.
Publicado: (2020)

Kinase Inhibitor Therapy in CML: It's What's Inside That Counts
por: Eide, Christopher A., et al.
Publicado: (2013)

Oral Cavity Squamous Cell Carcinoma Xenografts Retain Complex Genotypes and Intertumor Molecular Heterogeneity
por: Campbell, Katie M., et al.
Publicado: (2018)

Large‐scale topological disruption of chromosome territories 9 and 22 is associated with nonresponse to treatment in CML
por: Fabian‐Morales, Eunice, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hm02tnb4mqfm6t12o81dpcmduk